These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Author: Ohshima A, Yoshida K, Sato T, Miyazaki S, Yanagisawa M, Nakayama Y, Takahashi T, Mamiya S, Fukusima Y, Miura AB.
    Journal: Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405.
    Abstract:
    Seven patients with refractory and/or relapsed acute leukemia were treated with intermediate- or high-dose cytosine arabinoside (ara-C). One patient obtained complete remission and two achieved partial remission. We advocate intermediate ara-C in combination with anthracyclines for the treatment of patients with refractory and/or relapsed acute leukemia, because the toxicity is less severe than that of high-dose ara-C and the therapeutic results are not inferior to those obtained with high-dose ara-C. Kinetic differences in leukemic cells should be considered in order to obtain the maximum effect in intermediate- and high-dose ara-C therapy.
    [Abstract] [Full Text] [Related] [New Search]